Longeveron Inc (LGVN) - News Archive

Longeveron Inc.: Strategic Movements and Financial Insights Amidst ChallengesLongeveron Inc. a groundbreaking company in the field of cellular therapies, recently released a letter to its shareholders detailing its corp...

In a significant move aimed at bolstering its strategic framework and advancing its scientific endeavors, Longeveron Inc. a pioneering entity in cellular therapies, has announced the appointment of Devin Blass as Chief...

In the year of our Lord two thousand and twenty-three, within the hallowed halls of scientific discourse, the venerable firm, Longeveron, prepares to grace the illustrious Alliance for Regenerative Medicine’s distinguis...

The intersection of healthcare innovation and regulatory frameworks is a pivotal area in the pharmaceutical sciences, especially for diseases that are rare and challenging to treat, such as Hyoplastic Left Heart Syndrom...

Longeveron Inc. (NASDAQ: LGVN), a Miami-based clinical-stage biotechnology firm, has experienced significant fluctuations in its stock price over the past several weeks. Following the recent announcement of a $9 million...

In recent years, the pursuit of effective treatments for Alzheimer’s disease has prompted researchers to explore innovative therapeutic strategies, including cellular-based therapies. Longeveron, a biotechnology company...

Longeveron Inc, a leading biotechnology company, recently announced the closing of its registered direct offering, which successfully raised $9 million in gross proceeds. However, a closer look at the company s financia...

In a groundbreaking development in the field of regenerative medicine, Longeveron, a leading biopharmaceutical company, has announced that the U.S. Food and Drug Administration (FDA) has granted its product Lomecel-B th...

Longeveron Inc., a clinical stage regenerative medicine biotechnology company, has been making significant moves in the field of cellular therapies for life-threatening and chronic aging-related conditions. The recent a...

Longeveron Inc shares have indeed been a source of frustration for investors this year. However, this has not deterred the clinical stage regenerative medicine biotechnology company from forging ahead. On May 27, 2024,...

Longeveron Unveils Promising Advances in Treatments for HLHS and Alzheimer s Disease Miami, Dec. 20, 2023 - Longeveron Inc. (NASDAQ: LGVN), a pioneering clinical-stage biotechnology company, continues to make significan...

Longeveron Announces Contract Development and Manufacturing Business and First ContractLongeveron, a leading biotechnology company specializing in regenerative medicine, has recently announced the launch of its new cont...

In a groundbreaking development that has stimulated optimism and excitement in the scientific community, data from CLEAR MIND, a phase 2a clinical trial conducted by Longeveron evaluating the potential of Lomecel-B in A...

Miami-based biotechnology company, Longeveron Inc., recently announced the closing of a public offering that raised $5.25 million in gross proceeds. While this news may initially seem positive, a closer examination of t...

In a recent press release, Longeveron Inc., a leading biotechnology company specializing in regenerative medicine, announced the completion of a successful $5.15 million public offering. The company also revealed the pa...

Miami-based biotechnology company, Longeveron Inc. (NASDAQ: LGVN), recently issued a letter to shareholders highlighting its corporate strategy, clinical pipeline, and 2024 key priorities and goals. The company s CEO ex...

MIAMI, Dec. 22, 2023 - Longeveron Inc. (NASDAQ: LGVN), a leading clinical stage biotechnology company focused on developing cellular therapies for life-threatening and chronic aging-related conditions, announced today t...

Longeveron Announces $2.36 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules, Advancing Life-Saving Cellular Therapies in MiamiMiami, Dec. 21, 2023 - Longeveron Inc. (NASDAQ: LGVN), a leading bi...

Longeveron Inc. (NASDAQ: LGVN), a leading clinical-stage biotechnology company specializing in cellular therapies for life-threatening and chronic aging-related conditions, has recently revealed new encouraging clinical...

Miami-based biotechnology company, Longeveron Inc. (NASDAQ: LGVN), has made a significant stride in its mission to revolutionize the treatment of life-threatening and chronic aging-related conditions. Longeveron recentl...